CA2556759A1 - Combinaisons de beta-lapachone et de medicament en phase s pour le traitement du cancer - Google Patents

Combinaisons de beta-lapachone et de medicament en phase s pour le traitement du cancer Download PDF

Info

Publication number
CA2556759A1
CA2556759A1 CA002556759A CA2556759A CA2556759A1 CA 2556759 A1 CA2556759 A1 CA 2556759A1 CA 002556759 A CA002556759 A CA 002556759A CA 2556759 A CA2556759 A CA 2556759A CA 2556759 A1 CA2556759 A1 CA 2556759A1
Authority
CA
Canada
Prior art keywords
pharmaceutically acceptable
acceptable salt
lapachone
cancer
phase drug
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002556759A
Other languages
English (en)
Inventor
Chiang J. Li
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Arqule Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US11/060,747 external-priority patent/US20050192360A1/en
Priority claimed from US11/068,459 external-priority patent/US20050197406A1/en
Application filed by Individual filed Critical Individual
Publication of CA2556759A1 publication Critical patent/CA2556759A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Des cancers et/ou des tumeurs malignes peuvent être traités par administration d'un médicament en phase G1/S, de préférence un .beta.-lapachone, ou un sel pharmaceutiquement acceptable, un promédicament, un métabolite, un analogue ou un dérivé de celui-ci, combiné avec un médicament en phase S, avantageusement de la gemcitabine. Cette combinaison d'un médicament en phase G1/S avec un médicament en phase S permet d'obtenir un traitement incroyablement efficace du cancer. Cette invention porte sur des procédés de traitement de cancers par administration d'une combinaison d'un médicament en phase G1/S et d'un médicament en phase S, sur des compositions pharmaceutiques contenant la combinaison de médicaments utilisés dans ces procédés, ainsi que sur des kits pharmaceutiques.
CA002556759A 2004-02-23 2005-02-23 Combinaisons de beta-lapachone et de medicament en phase s pour le traitement du cancer Abandoned CA2556759A1 (fr)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US54728704P 2004-02-23 2004-02-23
US60/547,287 2004-02-23
US11/060,747 US20050192360A1 (en) 1999-04-14 2005-02-18 Method of treatment of pancreatic cancer
US11/068,459 2005-02-18
US11/060,747 2005-02-18
US11/068,459 US20050197406A1 (en) 1999-04-14 2005-02-18 Method of treatment of lung cancer
PCT/US2005/005620 WO2005082354A1 (fr) 2004-02-23 2005-02-23 Combinaisons de beta-lapachone et de medicament en phase s pour le traitement du cancer

Publications (1)

Publication Number Publication Date
CA2556759A1 true CA2556759A1 (fr) 2005-09-09

Family

ID=34916185

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002556759A Abandoned CA2556759A1 (fr) 2004-02-23 2005-02-23 Combinaisons de beta-lapachone et de medicament en phase s pour le traitement du cancer

Country Status (4)

Country Link
EP (1) EP1727536A1 (fr)
JP (1) JP2007523215A (fr)
CA (1) CA2556759A1 (fr)
WO (1) WO2005082354A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050187288A1 (en) * 2004-02-20 2005-08-25 Chiang Li Beta-lapachone and methods of treating cancer
WO2005082359A2 (fr) * 2004-02-20 2005-09-09 Arqule, Inc. Procede de traitement du cancer du pancreas
KR101752697B1 (ko) * 2015-04-17 2017-07-03 (주)나디안바이오 나프토퀴논계 화합물을 유효성분으로 포함하는 췌장염 예방 및 치료용 조성물
CN110478363B (zh) * 2019-08-22 2022-09-06 北京大学 cIMP的药物新用途

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4244141B2 (ja) * 2000-11-07 2009-03-25 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド 血液腫瘍および血液癌を処置する方法
AU2002226650A1 (en) * 2001-01-18 2002-07-30 Arnold Hoffman Redox therapy for tumors
JP2005538981A (ja) * 2002-07-17 2005-12-22 アーキュル， インコーポレイテッド 活性化チェックポイント療法およびこれらの使用方法

Also Published As

Publication number Publication date
EP1727536A1 (fr) 2006-12-06
WO2005082354A1 (fr) 2005-09-09
JP2007523215A (ja) 2007-08-16

Similar Documents

Publication Publication Date Title
US20010016329A1 (en) Methods and compositions for overcoming resistance to biologic and chemotherapy
WO2019073296A1 (fr) Formulations liposomales de bisantrène ou de dérivés ou analogues de celui-ci
US20090274773A1 (en) Antiproliferative combination comprising cyc-682 and a cytotoxic agent
CA2556759A1 (fr) Combinaisons de beta-lapachone et de medicament en phase s pour le traitement du cancer
EP2101790B1 (fr) Combinaison comprenant une sapacitibine (2'-cyano-2'-desoxy-n4-palmitoyl-1-bêta-d-arabinofuranosyl-cytosine) et un agent cytotoxique
CA2556794A1 (fr) Le beta-lapachone est un agent anticancereux a large spectre
CA2556789A1 (fr) Utilisation de beta-lapachone pour traiter des tumeurs hematologiques
EP2033640A2 (fr) Béta-lapachone pour le traitement du cancer des poumons
Ziemba et al. Development of an Oral Form of Azacytidine: 2′ 3′ 5′ Triacetyl‐5‐Azacytidine
US20050192247A1 (en) Method of treating cancers
WO2007132220A1 (fr) Combinaison de 4-hétér0aryl-pyrimidine amine substituée en 2 et d'un médicament cytotoxique, son utilisation dans le traitement d'un trouble prolifératif
EP2033638A2 (fr) Béta-lapachone pour le traitement du cancer pancréatique
US20050192360A1 (en) Method of treatment of pancreatic cancer
US20050197405A1 (en) Treatment of hematologic tumors and cancers with beta-lapachone, a broad spectrum anti-cancer agent
Raymond et al. Phase I study of daily times five topotecan and single injection of cisplatin in patients with previously untreated non-small-cell lung carcinoma
US20050197406A1 (en) Method of treatment of lung cancer
Liu et al. TCH-1030 targeting on topoisomerase I induces S-phase arrest, DNA fragmentation, and cell death of breast cancer cells
EP2033639A2 (fr) Béta-lapachone pour le traitement du cancer du colon
US20050192361A1 (en) Method of treatment of colon cancer
US20050222246A1 (en) Beta-lapachone is a broad spectrum anti-cancer agent
Skubitz A phase I study of ambulatory continuous infusion paclitaxel
De Jonge et al. Phase I and pharmacokinetic studies of PNU-159548, a novel alkycycline, administered intravenously to patients with advanced solid tumours
Wang et al. Reversal effect of nimodipine on cytarabine-resistant HL60 cells associated with triggering apoptosis
Schwendener et al. Derivatives in Liposomes
EP1240922A2 (fr) Méthodes et composés de combattre la résistance à la thérapie biologique et chimique

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued
FZDE Discontinued

Effective date: 20091229